The spectrum of the mutations identified was generally consistent with the published data [37,38], although the incidence of PIK3CA alterations was lower (37%) compared to that in European patients with ER+/HER2− BC (7706/17,687, 44%) [33]. This evidence concerns the gene PIK3CA and breast cancer.